Investigational drug · Phase 3
CF102
Also called: Namodenoson
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Adenocarcinoma, Pancreatic Cancer, Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "CF102"
First trial start
2023
Mar 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CF102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Adenocarcinoma
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Cirrhosis
Approved drugs for the same conditions: Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CF102" as an intervention, largest first.
- Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisPivotal-lookingRecruiting
Can-Fite BioPharmaIndustry
NCT05201404 · 471 participants (planned) · Start Mar 15, 2023 · Primary completion Feb 2026
Drug: Namodenoson; Placebo · For: Hepatocellular Carcinoma; Cirrhosis
Sites: Dallas, Texas; Banja Luka, Bosnia and Herzegovina; Mostar, Bosnia and Herzegovina · 32 sites in all
- Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)Pivotal-lookingStatus unknown
Can-Fite BioPharmaIndustry
NCT04697810 · 114 participants (planned) · Start Dec 10, 2021 · Primary completion Apr 15, 2025
Drug: Namodenoson; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Banja Luka, Bosnia and Herzegovina; Prijedor, Bosnia and Herzegovina; Plovdiv, Bulgaria · 24 sites in all
Can-Fite BioPharmaIndustry
NCT02128958 · 78 participants · Start Sep 2014 · Primary completion Nov 27, 2017
Drug: CF102; Placebo · For: Hepatocellular Carcinoma
Sites: Aurora, Colorado; Dallas, Texas; Plovdiv, Bulgaria · 21 sites in all
- A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver DiseaseCompleted
Can-Fite BioPharmaIndustry
NCT02927314 · 60 participants · Start Nov 27, 2017 · Primary completion Mar 1, 2020
Drug: CF102; Placebo · For: Non-alcoholic Steatohepatitis (NASH)
Sites: Jerusalem, Israel; Nazareth, Israel; Petah Tikva, Israel
Can-Fite BioPharmaIndustry
NCT00790673 · 32 participants · Start Jul 2009 · Primary completion Jun 2011
Drug: CF 102; Placebo · For: Chronic Hepatitis C
Sites: Tel Aviv, Israel
Can-Fite BioPharmaIndustry
NCT06387342 · 20 participants (planned) · Start Nov 10, 2024 · Primary completion Jul 15, 2026
Drug: Namodenoson 25mg · For: Pancreatic Adenocarcinoma; Pancreatic Cancer
Sites: Petah Tikva, Israel
Can-Fite BioPharmaIndustry
NCT00790218 · 19 participants · Start Feb 2009 · Primary completion Dec 2012
Drug: CF102 · For: Hepatocellular Carcinoma
Sites: Tel Aviv, Israel
Newest research
PubMed records naming it or its code names, newest first.
- Endothelial SHMT2 Drives Pulmonary Vascular Remodeling Through Noncanonical Pathway in Pulmonary Hypertension.
Wang Q, Tian J, Liu D, et al. · Circulation 2026
- A3 Adenosine Receptor Agonists as Multisystem Disease Modifiers: From Molecular Signaling to Clinical Translation.
Fishman P · Biomolecules 2026
- The anti-obesity effect of namodenoson, an A3 adenosine receptor agonist.
Fishman P, Itzhak I, Safadi R, et al. · Int J Obes (Lond) 2026
- Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects.
Kaldjob-Heinrich L, Nuciforo S, Lemke S, et al. · Gastro Hep Adv 2025
- Structural insights into the agonist selectivity of the adenosine A3 receptor.
Oshima HS, Ogawa A, Sano FK, et al. · Nat Commun 2024
- The different effects of four adenosine receptors in liver fibrosis.
Yang L, Gao ZW, Wang X, et al. · Front Pharmacol 2024
Also in development for Pancreatic Adenocarcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- BL-8040Phase 32 trials
BioLineRx, Ltd. · Multiple Myeloma, Pancreatic Adenocarcinoma
- AB928Etrumadenant, ETRUMAPhase 24 trials
Arcus Biosciences, Inc. · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
- SelicrelumabPhase 22 trials
Roche (Genentech) · Metastatic Breast Cancer, Pancreatic Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.